ANALYSIS OF ADVERSE EFFECTS IN IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH JAK INHIBITORS IN A SINGLE CENTER

I. Pineiro, L. Ibarrola, G. Sada Urmeneta, U. Astigarraga Urkia, M. López I Gómez, J. Mendizabal, N. Del Val del Amo, L. Garrido Courel, I. Paniagua Zudaire, L. Horcada, R. Gutierrez, C. Fito-MantecaHospital Universitario de Navarra, Rheumatology, Pamplona, Spain Hospital Universitario de Arava, Rheumatology, Vitoria, Spain  Background Janus kinase (JAK)-inhibitors (JAKi) are anti-cytokine monoclonals against cellular targets and small molecule inhibitors of the JAK pathway approved for the treatment of diverse immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthritis (PsA). Safety data comes mostly from randomized controlled trials, with scarce long-term registry data. Therefore, we aimed to evaluate the major adverse events in patients treated with Janus kinase inhibitors in various immune-mediated inflammatory diseases (RA, PsA and SpA). Objectives To evaluate adverse events in patients treated with Janus kinase inhibitors in various immune-mediated inflammatory diseases (RA, PsA and SpA). Methods We reviewed 203 patients in Rheumatology department at Navarra University Hospital who underwent treatment with JAKi (Baricitinib, Filgotinib, Tofacitinib and Upadacitinib) and the significant adverse events occurred. Results Of our sample of 203 patients, 81,2% were diagnosed RA, 8,8% with PsA, 7,5% with SpA and the remaining 2,5% were indeterminate arthritis. We found that out of the patients diagnosed with RA, 10,83 % had a significant adverse event (22 events in total). A 0,5% had a myocardial infarction, 1,5% stroke, 2,1% arterial thrombosis, 2,1% venous thrombosis, 1,5% developed some type of malignancy and 3,6% reactivation of herpes zoster. One arterial thrombosis happened in the indeterminate arthritis group. Conclusion In our series, out of 203 patients treated with JAKi, 11,33% had a significant adverse event. The most common adverse event was the herpes zoster reactivation (3,44%), followed by arterial and venous thrombosis (2,46 and 1,97% respectively). Longer-term follow-up and greater number of patients are necessary to ratify these data. References: [1]Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immunemediated inflammatory diseases with Janus kinase inhibitors. Ann Rheum Dis. (2021) 80:71–87. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared. Keywords: Rheumatoid arthritis, Disease-modifying drugs (DMARDs), Safety DOI: 10.1136/annrheumdis-2023-eular.6317Citation: , volume 82, supplement 1, year 2023, page 1445Session: Rheumatoid arthritis - non biologic treatment and small molecules (Publication only)